The serotonergic system in motor and non-motor manifestations of Parkinson's disease

Experimental Brain Research

Volumn 230, Issue 4, 2013, Pages 463-476

  Huot, Philippe ^a,b   Fox, Susan H ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Depression; Dyskinesia; Parkinson's disease; Psychosis; Serotonin; Tremor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOZAPINE; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; LEVODOPA; METHYSERGIDE; MIRTAZAPINE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PICLOZOTAN; RASAGILINE; RITANSERIN; SARIZOTAN; SELEGILINE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TANDOSPIRONE; UNINDEXED DRUG;

ANXIETY; ANXIETY DISORDER; ARTICLE; DEGENERATIVE DISEASE; DEPRESSION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DYSKINESIA; EVIDENCE BASED MEDICINE; HUMAN; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ANIMALS; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; RECEPTORS, SEROTONIN; SEROTONERGIC NEURONS; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 84885637489     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-013-3621-2     Document Type: Article

References (204)

1. ACADIA (2013) ACADIA Pharmaceuticals announces expedited path to NDA filing for pimavanserin following meeting with FDA. http://phx.corporate-ir.net/ phoenix.zhtml?c=125180&p=irol-newsArticle&ID=1805706 Accessed 14th April 2013
2. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA (2008) Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 28:441-444
3. Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 21:1119-1122
4. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 667:295-299
5. Arai R, Karasawa N, Geffard M, Nagatsu I (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 195:195-198
6. Arai R, Karasawa N, Nagatsu I (1996) Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 706:177-179
7. Auff E, Birkmayer W, Brucke T et al (1987) Ritanserin in the treatment of tremor-dominant Parkinson's disease: a preliminary study. New Trends Clin Neuropharmacol 1:149-158
8. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67:416-421
9. Ballanger B, Klinger H, Eche J et al (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord 27:84-89
10. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 20:932-936
11. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152
12. Baron MS, Dalton WB (2003) Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Mov Disord 18:1208-1209
13. Bartoszyk GD, Van den Buuse M, Gerlach M, Riederer P (2006) Mechanism of the antidyskinetic efficacy of sarizotan in hemiparkinsonian rats [Abstract]. Mov Disord 21(Suppl 15):S495
14. Bennett JP Jr, Landow ER, Schuh LA (1993) Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 43:1551-1555
15. Bennett JP Jr, Landow ER, Dietrich S, Schuh LA (1994) Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 9:409-414
16. Berding G, Brucke T, Odin P et al (2003) [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin 42:31-38
17. Berger B (1978) In vitro uptake of dopamine in serotoninergic nerve terminals: a fluorescence histochemical study on vibratome sections of the rat cerebral cortex. Adv Biochem Psychopharmacol 19:405-408
18. Berger B, Glowinski J (1978) Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures. Brain Res 147:29-45
19. Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829-1834
20. Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD (2006) MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23:2669-2676
21. Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87:1645-1658
22. Bishop C, George JA, Buchta W et al (2012) Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 36:2839-2848
23. Boileau I, Warsh JJ, Guttman M et al (2008) Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 23:1776-1780
24. Bonhaus D, MacFarland K, Willims H, Mills R (2009) Pimavanserin: a selective 5-HT2A inverse agonist has antipsychotic like activity in animal models of Parkinson's disease (PD) and reduces psychotic symptoms in PD patients [Abstract]. Soc Neurosci
25. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G (1994) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17:73-82
26. Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352:1112-1120
27. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
28. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134
29. Brandstadter D, Oertel WH (2002) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 58:160-161
30. Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 94:137-146
31. Burstein ES, Ma J, Wong S et al (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287
32. Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
33. Caley CF, Friedman JH (1992) Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53:278-282
34. Caretti V, Stoffers D, Winogrodzka A et al (2008) Loss of thalamic serotonin transporters in early drug-naive Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. J Neural Transm 115:721-729
35. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D (2007) Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 27:8011-8022
36. Carlsson T, Carta M, Munoz A, Mattsson B, Winkler C, Kirik D, Bjorklund A (2009) Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132:319-335
37. Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833
38. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A (2008) Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 172:465-478
39. Ceravolo R, Nuti A, Piccinni A et al (2000) Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 55:1216-1218
40. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ (1998) Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci 861:288-289
41. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM (2007) Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 20:161-165
42. Cheng AV, Ferrier IN, Morris CM et al (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106:50-55
43. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54:691-699
44. Chung YC, Kim SR, Park JY et al (2011) Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60:963-974
45. Connemann BJ, Schonfeldt-Lecuona C (2004) Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry 49:73
46. Dahlstroem A, Fuxe K (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 232(Suppl):231-255
47. D'Amato RJ, Zweig RM, Whitehouse PJ et al (1987) Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22:229-236
48. Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89
49. Descarries L, Riad M (2012) Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci 367:2416-2425
50. Dewey RB Jr, O'Suilleabhain PE (2000) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 55:1753-1754
51. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003) Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60:601-605
52. Dupre KB, Eskow KL, Negron G, Bishop C (2007) The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135-143
53. Dupre KB, Eskow KL, Barnum CJ, Bishop C (2008) Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55:1321-1328
54. Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229:288-299
55. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y (1995) Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45:1855-1858
56. Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87:306-314
57. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-DOPA-induced dyskinesia in hemiparkinsonian rats. Synapse 63:610-620
58. Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 7:125-131
59. Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12:483-496
60. Fahn S (2008) The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23(Suppl 3):S497-S508
61. Fahn S, Libsch LR, Cutler RW (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 14:427-455
62. Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease. Macmillan Healthcare Information, Florham Park, pp 153-163
63. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH (2003) Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18:510-514
64. Fernandez HH, Trieschmann ME, Friedman JH (2004) Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27:4-5
65. Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. Can J Neurol Sci 37:86-95
66. Fregni F, Santos CM, Myczkowski ML et al (2004) Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 75:1171-1174
67. French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 353:2041-2042
68. Friedman JH (1992) Fluoxetine in Parkinson's disease [Abstract]. Mov Disord 7(Suppl 1):102
69. Friedman JH, Factor SA (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15:201-211
70. Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 39:1219-1221
71. Friedman JH, Berman RM, Goetz CG et al (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 21:2078-2081
72. Frisina PG, Haroutunian V, Libow LS (2009) The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 15:144-148
73. Gatto EM, Fernandez Pardal M, Micheli F (1994) Exacerbation of parkinsonism caused by fluoxetine. Medicina (B Aires) 54:182
74. Gerard C, Martres MP, Lefevre K et al (1997) Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 746:207-219
75. Gil S, Park C, Lee J, Koh H (2010) The roles of striatal serotonin and L: -amino-acid decarboxylase on L: -DOPA-induced Dyskinesia in a Hemiparkinsonian rat model. Cell Mol Neurobiol 30:817-825
76. Gil SJ, Park CH, Lee JE, Minn YK, Koh HC (2011) Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats. Brain Res Bull 84:151-156
77. Gimenez-Roldan S, Navarro E, Mateo D (2003) Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease. Rev Neurol 36:401-404
78. Goetz CG, Damier P, Hicking C et al (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 22:179-186
79. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427
80. Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S (2002) Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 9:125-126
81. Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-DOPA in parkinsonian monkeys. Parkinsonism Relat Disord 15:445-452
82. Guttman M, Boileau I, Warsh J et al (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 14:523-528
83. Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllyla VV (2001) [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 16:124-130
84. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990a) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 510:104-107
85. Halliday GM, Li YW, Blumbergs PC et al (1990b) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27:373-385
86. Hammerstad JP, Carter J, Nutt JG, Casten GC, Shrotriya RC, Alms DR, Temple D (1986) Buspirone in Parkinson's disease. Clin Neuropharmacol 9:556-560
87. Hauser RA, Zesiewicz TA (1997) Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 12:756-759
88. Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson's disease: non-L-DOPA-responsive problems dominate at 15 years. Mov Disord 20:190-199
89. Henderson J, Yiannikas C, Graham JS (1992) Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease. Clin Exp Neurol 29:277-282
90. Hildebrand J, Delecluse F (1987) Effect of ritanserin, a selective serotonin-S2 antagonist, on parkinsonian rest tremor. Curr Ther Res 41:298-300
91. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7:726-735
92. Hornykiewicz O (2002) L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23:65-70
93. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
94. http://www.clinicaltrials.gov/ (NCT01174004) A study of the safety and efficacy of pimavanserin in patients with Parkinson's disease psychosis. Accessed 14th April 2013
95. Huot P, Johnston TH, Darr T et al (2010a) Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 25:1399-1408
96. Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM (2010b) Regulation of cortical and striatal 5-HT(1A) receptors in the MPTP-lesioned macaque. Neurobiol Aging 1:491-512. doi: 10.1016/j.neurobiolaging. 2010.1009.1011
97. Huot P, Fox SH, Brotchie JM (2011a) The serotonergic system in Parkinson's disease. Prog Neurobiol 95:163-212
98. Huot P, Fox SH, Newman-Tancredi A, Brotchie JM (2011b) Anatomically-selective 5-HT1A and 5-HT2A therapies for Parkinson's disease-an approach to reducing dyskinesia without exacerbating parkinsonism? J Pharmacol Exp Ther 339:1-7
99. Huot P, Johnston TH, Lewis KD et al (2011c) Characterization of 3,4-methylenedioxymethamphetamine (mdma) enantiomers in vitro and in the mptp-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of on-time. J Neurosci 31:7190-7198
100. Huot P, Johnston TH, Visanji NP et al (2012a) Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov Disord 27:735-742
101. Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM (2012b) 5-HT(2A) receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiol Aging 33:194.e195-115
102. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P (2003) 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 23:9107-9115
103. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P (2006) In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 319:1225-1234
104. Jakeman LB, To ZP, Eglen RM, Wong EH, Bonhaus DW (1994) Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1. Neuropharmacology 33:1027-1038
105. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140
106. Juncos JL, Arvanitis L, Sweitzer D, Yeung P, Jewart RD (1999) Quetiapine improves psychotic symptoms associated with Parkinson's disease. Neurology 52(Suppl 2):A262
107. Kannari K, Kurahashi K, Tomiyama M et al (2002) Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54:133-137
108. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ (2004) Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 75:295-297
109. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY (2003) Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 44:870-876
110. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131:120-131
111. Klawans HL, Ringel SP (1973) A clinical study of methysergide in Parkinsonism: evidence against a serotonergic mechanism. J Neurol Sci 19:399-405
112. Kleedorfer B, Lees AJ, Stern GM (1991) Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 54:376-377
113. Kohl Z, Winner B, Ubhi K et al (2012) Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 35:10-19
114. Kuan WL, Zhao JW, Barker RA (2008) The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology 197:279-293
115. Kuno A, Ogawa T, Ikeguchi K, Fujimoto K, Nakano I (2001) Deterioration of parkinsonian symptoms and psychosis after fluvoxamine medication. Neurol Med 54:157-160
116. Lavoie B, Parent A (1990) Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 299:1-16
117. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR (2003) SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 18:552-554
118. Leo RJ (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449-454
119. Linazasoro G (2000) Worsening of Parkinson's disease by citalopram. Parkinsonism Relat Disord 6:111-113
120. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112:1465-1476
121. Lopez-Meza E, Ruiz-Chow A, Ramirez-Bermudez J (2005) Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci 17:421-422
122. Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, LeWitt PA, Chase TN (1986) Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 9:373-378
123. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132
124. Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194:66-75
125. Maeda T, Yoshida J, Kudo K, Nagata K (2009) Systemic L-DOPA deplete the striatal serotonin release in rats with nigro-striatal dopaminergic denervation [Abstract]. Mov Disord 24(Suppl 1):S355-S356
126. Maeda T, Yoshida J, Kudo K, Nagata K, Yamamoto M (2010) Systemic L-DOPA deplete the striatal serotonin release in rats with nigro-striatal dopaminergic denervation [Abstract]. Mov Disord 25(Suppl 2):S416
127. Maertens de Noordhout A, Delwaide PJ (1986) Open pilot trial of ritanserin in parkinsonism. Clin Neuropharmacol 9:480-484
128. Maloteaux JM, Luabeya MK, Laterre EC, Javoy-Agid F, Agid Y, Laduron PM (1985) S2-serotonin receptors in frontal cortex of parkinsonian patients [Abstract]. J Neurol 32(Suppl):108
129. Maloteaux JM, Laterre EC, Laduron PM, Javoy-Agid F, Agid Y (1988) Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 3:255-262
130. Mann DM, Yates PO (1983) Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol 9:3-19
131. Marin C, Aguilar E, Rodriguez-Oroz MC, Bartoszyk GD, Obeso JA (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology 204:241-250
132. Marsden CD (1982) The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 32:514-539
133. McCance-Katz EF, Marek KL, Price LH (1992) Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42:1813-1814
134. Meco G, Marini S, Linfante I, Modarelli F, Agnoli A (1988) Controlled single-blind crossover study of ritanserin and placebo in L-DOPA-induced dyskinesias in Parkinson's disease. Curr Ther Res 43:262-270
135. Meco G, Bonifati V, Fabrizio E, Vanacore N (1994) Worsening of parkinsonism with fluvoxamine - two cases. Hum Psychopharmacol 9:439-441
136. Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L (2003) Mirtazapine in L-DOPA-induced dyskinesias. Clin Neuropharmacol 26:179-181
137. Meco G, Stirpe P, Edito F, Purcaro C, Valente M, Bernardi S, Vanacore N (2009) Aripiprazole in L-DOPA-induced dyskinesias: a one-year open-label pilot study. J Neural Transm 116:881-884
138. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 12:39-45
139. Menza MM, Palermo B, Mark M (1999) Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 11:141-144
140. Menza M, Marin H, Kaufman K, Mark M, Lauritano M (2004) Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 16:315-319
141. Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29:331-337
142. Mills R, Revell S, Bahr D, Williams H, Johnson A, Friedman JH (2008) A double-blind, placebo-controlled, dose-escalation trial of pimavanserin in Parkinson's disease and psychosis [Abstract]. Mov Disord 23(Suppl 1):S221-S222
143. Montastruc JL, Fabre N, Blin O, Senard JM, Rascol O, Rascol A (1995) Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord 10:355-357
144. Morgante L, Epifanio A, Spina E et al (2002) Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 23(Suppl 2):S89-S90
145. Muller T, Olanow CW, Nutt J, Hicking C, Laska E, Russ H (2006) The PADDY-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in Parkinson's disease patients. Mov Disord 21(Suppl. 15):S591
146. Munoz A, Li Q, Gardoni F et al (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131:3380-3394
147. Murai T, Muller U, Werheid K et al (2001) In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13:222-228
148. Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177:111-115
149. Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis 41(2):585-590
150. Nevalainen N, Af Bjerken S, Lundblad M, Gerhardt GA, Stromberg I (2011) Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. J Neurochem 118(1):12-23
151. Nichols DE, Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614-1641
152. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
153. Oh JD, Bibbiani F, Chase TN (2002) Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 177:557-564
154. Ohama E, Ikuta F (1976) Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 34:311-319
155. Olanow CW, Damier P, Goetz CG et al (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27:58-62
156. Ostock CY, Dupre KB, Eskow Jaunarajs KL et al (2011) Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 61:753-760
157. Pact V, Giduz T (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 53:1154
158. Palhagen SE, Carlsson M, Curman E, Walinder J, Granerus AK (2008) Depressive illness in Parkinson's disease-indication of a more advanced and widespread neurodegenerative process? Acta Neurol Scand 117:295-304
159. Papavasilliou PS, Cotzias GC, McDowell FH, Rosal VL, Sheehan PJ (1978) Cyproheptadine in levodopa-induced dyskinesia in parkinsonism. Clin Pharmacol Ther 23:195-198
160. Paquette MA, Lewis JR, Meshul CK, Johnson SW, Berger SP (2009) Effects of 5-HT1A agonism and NDMA antagonism on L-DOPA-induced dyskinesia and sensorimotor behavior in the 6-OHDA rat [Abstract]. Soc Neurosci
161. Paquette MA, Martinez AA, Macheda T, Giuffrida A (2010) NMDA antagonism versus 5-HT1A agonism: suppressing L-DOPA-induced dyskinesia without exacerbating parkinsonism in the 6-OHDA rat [Abstract]. Soc Neurosci
162. Parent A, Descarries L, Beaudet A (1981) Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. Neuroscience 6:115-138
163. Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 340:757-763
164. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50:743-755
165. Paumier KL, Siderowf AD, Auinger P et al (2012) Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Mov Disord 27:880-887
166. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ (2010) Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 133:3434-3443
167. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P (2010a) Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 40:216-221
168. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P (2010b) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75:1920-1927
169. Pollak P, Tison F, Rascol O et al (2004) Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75:689-695
170. Prueter C, Habermeyer B, Norra C, Kosinski CM (2003) Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov Disord 18:712-713
171. Raisman R, Cash R, Agid Y (1986) Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 36:556-560
172. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-DOPA. Clin Neuropharmacol 25:21-24
173. Rascol O, Damier P, Goetz CG et al (2006) A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of L-DOPA-induced dyskinesia associated with Parkinson's disease: the Paddy-1 study. Mov Disord 21(Suppl. 15):S492-S493
174. Reddy S, Factor SA, Molho ES, Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17:676-681
175. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314-1322
176. Riahi G, Morissette M, Parent M, Di Paolo T (2011) Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 33(10):1823-1831
177. Rich SS, Friedman JH, Ott BR (1995) Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 56:556-559
178. Richard IH, Kurlan R (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 49:1168-1170
179. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 48:1070-1077
180. Richard IH, McDermott MP, Kurlan R et al (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229-1236
181. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
182. Ritter JL, Alexander B (1997) Retrospective study of selegiline- antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry 9:7-13
183. Roberts C (2006) ACP-103, a 5-HT2A receptor inverse agonist. Curr Opin Investig Drugs 7:653-660
184. Rylander D, Parent M, O'Sullivan SS et al (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68:619-628
185. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328
186. Schonfeldt-Lecuona C, Connemann BJ (2004) Aripiprazole and Parkinson's disease psychosis. Am J Psychiatry 161:373-374
187. Seeman P, Tallerico T (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876-884
188. Seppi K, Weintraub D, Coelho M et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26(Suppl 3):S42-S80
189. Sharp SI, Ballard CG, Ziabreva I et al (2008) Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 26:330-338
190. Strecker K, Wegner F, Hesse S et al (2011) Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. J Neurol 258:19-26
191. Suzuki K, Okada K, Wakuda T et al (2010) Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine. PLoS ONE 5:e9260
192. Tani Y, Ogata A, Koyama M, Inoue T (2010) Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. Eur J Pharmacol 649:218-223
193. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G (2000) Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 15:986-989
194. Thomas AA, Friedman JH (2010) Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 33:14-16
195. Trappler B, Friedman S (1998) Treatment of depression in Parkinson's disease in the very old. J Pharm Tech 14:110-115
196. Trosch RM, Group CC (1996) Clozapine use in Parkinson's disease [Abstract]. Neurology 46:A375-A376
197. Trosch RM, Friedman JH, Lannon MC et al (1998) Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 13:377-382
198. Vanover KE, Weiner DM, Makhay M et al (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)- N′-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)- dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910-918
199. Vanover KE, Betz AJ, Weber SM et al (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 90:540-544
200. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 21:1879-1891
201. Weiner WJ, Minagar A, Shulman LM (2000) Quetiapine for l-DOPA-induced psychosis in PD. Neurology 54:1538
202. Wermuth L, Sorensen PS, Timm S et al (1998) Depression in idiopathic Parkinson's disease treated with citalopram-A placebo-controlled trial. Nord J Psychiatry 52:163-169
203. Wickremaratchi M, Morris HR, Ali IM (2006) Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 21:1538-1539
204. Wilson JM, Levey AI, Rajput A et al (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-726